ReviewJournal of thrombosis and thrombolysis
Pharmacogenetics and anticoagulant therapy.
Review in Journal of thrombosis and thrombolysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 30 citations in OpenAlex.
- Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.Thrombosis and haemostasis · 2012Trial
- Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.Journal of thrombosis and thrombolysis · 2011Trial
- Pharmacogenetics of warfarin dosing in patients of African and European ancestry.Pharmacogenomics · 2018Review
- Article
- VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.European journal of clinical pharmacology · 2008Article
- Warfarin: a case history in pharmacogenetics.Heart (British Cardiac Society) · 2005Article
- Common VKORC1 and GGCX polymorphisms associated with warfarin dose.The pharmacogenomics journal · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Warfarin and other coumarins are metabolized by the cytochrome P450 2C9 complex. Common single-nucleotide polymorphisms (SNPs) in this enzyme are associated with an exaggerated elevation in the INR during warfarin initiation and an increased risk of bleeding. These observations suggest that patients known to carry the putative SNPs should be started on lower doses of warfarin therapy or have their INR values monitored more frequently during warfarin initiation. Such clinical variables as age, body surface area, and concomitant medications also play important roles in determining the maintenance dose of warfarin. Thus, a comprehensive dosing algorithm offers the most promising approach to estimating the therapeutic dose of warfarin a priori and to preventing hemorrhage during warfarin induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.